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Altered Composition of Urinaiy Heparan Sulfate in 
Patients with COPD
CHRIS H. van de LEST, ELLY M. VERSTEEG, JACQUES H. VEERKAMP, JO H. BERDEN, 
JACOB van den BORN, LEO HEUNKS, JAN-WILLEM J. LAMMERS, CEES L. van HERWAARDEN, 
P. N. RICHARD DEKHUIJZEN, and TOIN H. van KUPPEVELT
Departments of Biochemistry, Nephrology, and Pulmonary Diseases, University of Nijmegen, Nijmegen, the Netherlands
In patients with emphysema the integrity of the extracellular matrix (connective tissue skeleton) is 
compromised. In this study we analyzed glycosaminoglycans, which are main constituents of this matrix, 
in urines from patients with chronic obstructive pulmonary disease (COPD)/emphysema. Glycosami­
noglycans (GAGs) were purified by anion exchange chromatography and quantified using the 1,9-di- 
methyl methylene blue assay. Heparan sulfate (HS) was assayed using three different chemical methods: 
digestion with heparitinase or with nitrous acid and by use of an adapted 1,9-dimethylmethylene blue 
assay. A specific epitope on the HS molecule, defined by the monoclonal antibody JM403, was deter­
mined using an inhibition enzyme immunoassay. In patients with COPD total urinary glycosaminogly- 
can and HS content were not altered. The JM403 epitope of HS, however, was greatly decreased in 
patients (0.6 versus 4.1 units/mg creatinine for control subjects, p < 0.0001). A similar pattern was 
observed when patients with bronchial carcinoma with and without emphysema were compared (0.4 
versus 2.4 units/mg creatinine respectively, p < 0.0005). Patients with sarcoidosis did not show a de­
creased epitope content. These results indicate a structural change or an altered processing of the HS 
molecule in patients with emphysema. Taking into consideration the importance of HS for the stability 
of the alveolar extracellular matrix, this change may be associated with the pathogenesis of emphy­
sema. van de Lest CH, Versteeg EM, Veerkamp JH, Berden JH, van den Born J, Heunks L, Lammers 
J-WJ, van Herwaarden CL, Dekhuijzen PNR, van KuppeveltTH. Altered composition of urinary 
heparan sulfate in patients with COPD. am j resp ir c r i t  ca re  med i 9 9 6 ; 1 5 4 :9 5 2 - 8 .
Airspace enlargement, destruction of alveoli, and loss of elasticity 
are the hallmarks of pulmonary emphysema. A loss of the in­
tegrity of the extracellular matrix is probably underlying the dis­
ease. The vast majority of research has focused on elastin. Break­
down of elastin, however, has not been unequivocally demon­
strated in human emphysematous lung tissue (1), nor is there con­
sensus about an increase in elastin-derived peptides in serum or 
urine of patients. Elevated levels of elastin-derived peptides have 
(2, 3), and have not (4-6) been observed. In laboratory animals, 
emphysema can be induced with and without destruction of elas­
tin (1).
Other alveolar extracellular matrix molecules like collagens, 
proteoglycans, laminin, and fibronectin may also be of impor­
tance in the pathogenesis of emphysema. Proteoglycans deserve 
special attention because they play a key role in the integrity of
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the alveolar wall. They are involved in the fibrillogenesis and me­
chanical characteristics of elastin and collagen (7-9), they bind 
and modulate growth factors and cytokines (10), and they are 
powerful inhibitors of proteases, including human leukocyte elas- 
tase (11-13).
Proteoglycans are macromolecules consisting of a core pro­
tein to which negatively charged glycosaminoglycans (GAGs) are 
attached. GAGs are a class of long unbranched polysaccharides, 
consisting o f repeating disaccharides o f which one is an amino 
sugar residue and the other an uronic acid residue. In the alveo­
lar wall, different types of GAGs are present (14, 15), including 
heparan sulfate (HS) which is located in basement membranes 
and on cell surfaces. Alterations in lung GAGs have been de­
scribed in experimental as well as human emphysema (16-21). 
The results o f  these studies, however, are contradictory, likely 
due to differences in experimental setup. In human lung, for in­
stance, an increase (16) and a decrease (17) in the percentage of 
hyaluronic acid have been found; also in human lung an increase 
(18) and no increase (19) in the glucosamine/galactosamine ratio 
has been demonstrated.
In this study we have analyzed the urinary excretion of GAGs 
from patients with chronic obstructive pulmonary disease (COPD) 
emphysema, with special emphasis on HS. For comparison, we 
also studied patients with bronchial carcinoma with and with­
out emphysema, and patients with sarcoidosis. It was found that 
the presence o f a specific epitope o f HS is considerably reduced 
in urine o f emphysematous patients, despite an unchanged total 
HS content.
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TABLE 1
PHYSIOLOGIC DATA OF PATIENTS WITH COPD
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FEVt FEVi
Patient
Code
Age (yr), 
Sex
BMÎ
(kg/m2)
TLC
(% pred)
RV
(% pred)
(% pred) 
before S
(% pred) 
after S
Kco
(% pred)
Pao?
(kPa)
Pacô2
(/cPa)
Pack-
years
JG 51, M 23.3 102 97.5 35 42 n 7.09 4 21
BR 63, M 19.6 111 135 43 49 54 ND ND 30
O 71, M 24.7 138 211 31 31 54 ND ND 20
HS 71, F 24.6 104 67 45 55 31 12,1 4.6 5
Jl 65, M 23.4 104 135 23 23 41 9.5 4.7 40
V 82, M 29.6 132 177 46 54 69 6,8 6.5 40
HX 56, F 24.9 125 171 19 21 20 8.1 5.9 40
JA 57, F 24.7 94 136 28 27 50 7,8 8.1 30
IB 70, M 18.1 106 102 30 32 53 7,9 5.7 0
JH 60, M 20,5 110 196 n 14 28 8.7 6.2 30
JD 62, M 29 121 216 26 24 67 14.2 4.3 35
HZ 50, M 20.1 110 224 31 37 58 11 4.6 30
H 65, M 28.7 107 110 41 46 40 9.2 5.1 45
HU 74, M 20.9 140 174 31 33 38 11,9 4.9 20
JE 67, M 21.3 117 139 43 43 29 10.3 4,9 35
HP 70, M 22.9 113 152 21 21 49 9.7 4.9 13
HV 71, M 27.4 109 153 24 24 73 8.4 6.3 12
W 61, M 17.4 117 198 19 20 21 7.8 6,2 40
HR 79, M 24,7 94 96 55 57 61 11.1 4.9 10
HT 60, F 18 116 159 26 33 35 8.9 5.0 25
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Definition of abbreviations: BMI = body mass index (weight/length2); TLC = total lung capacity; RV = residual volume; FEV| = forced 
expiratory volume in one second; S = salbutamol; Kco = difusion capacity for carbon monoxide corrected for alveolar volume; % pred = 
percentage of the predicted value; ND = not determined.
METHODS
Patients and Control Subjects
Three groups o f  patients and control subjects were studied: Group 1, 
patients with C O PD  and m atched control subjects; Group 2, patients 
with bronchial carcinom a with and w ithout emphysema; and Group 3, 
patients with sarcoidosis and m atched con tro l subjects.
Physiologic data for individual patients are given in Tables 1-3. In 
all groups subjects with cardiovascular, alcohol-related, or renal diseases 
were excluded. Patients with di-antitrypsin deficiency were also excluded. 
Control subjects did not show  any sign o f  pulm onary disease, nor any  
other disease. Patients and control subjects were matched for sex, age , 
and sm oking habit. All subjects were studied  according to guidelines
o f  the Com m ittee o f  Medical Ethics o f  the University H ospital N ijm e­
gen and gave informed consent.
Static and dynam ic lung function tests were performed with a wet 
spirometer and with a closed-circuit helium -dilution m ethod (P u lm o-  
net III; Sensormedics, Bilthoven, the Netherlands). D iffu sion  capacity  
(K co) was measured with the single breath-holding carbon m onoxide  
method (Sensormedics 2450) and was corrected for actual hem oglobin . 
M easurements were performed at least 12 h after sm oking. Predicted  
spirometric values were derived from the European Com m unity for Steel 
and Coal (E.C.S.C.) standards (22).
Arterial blood sam ples were taken after the patients had been sitting  
for at least 15 min. Pao2 and P a c o 2 were measured with a C orning Pli 
127 blood gas analyzer (Corning Glass, M edfield, M A).
TABLE 2
PHYSIOLOGIC DATA OF PATIENTS WITH BRONCHIAL CARCINOMA,
WITH OR WITHOUT EMPHYSEMA
FEVi FEVi
Patient Age (yr) TLC RV (% pred) (% pred) Kco Pao2 Paco2 Pack-
Code Sex (% pred) (% pred) before
Patients with bronchial carcinoma and emphysema
15 64, F 113 119 44
67 60, M 94 114 61
72 75, M 136 120 64
44 58, M 116 157 64 
71 66, M 112 105 42
45 70, M 96 100 75 
58 77, M 109 95 80 
18 78, M 132 89 70
Patients with bronchial carcinoma, without emphysema
21 58, M 79 65 76
65 68, M 102 106 75
37 72, M 96 86 104
41 96, M 93 103 75
3 68, M 85 78 71
8 81, M 103 81 110
56 64, M 66 65 47
39 63, M 98 110 71
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For definition of abbreviations, see Table 1.
* Nonsmoker.
rter S
■ t . . . . . .  -
(% pred)
. . .  ••• •••••• r r • *r.. i . . . t- ., — i.
(kPa) (kPa) year:
. , .  . ,-s. .
47 53 8.1 5.6 40
58 61 10.6 5.3 35
68 78 10.6 5.1 10
67 68 83 4.6 20
39 46 8.0 5,5 40
74 71 8.9 5.4 50
78 52 10.3 5.4 15
71 54 9.5 4.9 20
76 120 13.5 5.2 20
75 86 7.0 5.48 20
104 123 9.8 4.8 10
75 90 7.7 5.0 25
75 89 10.6 4.5 30
115 83 11.2 4.9 ★
50 93 9.2 5.6 40
75 104 8.2 5,3 30
1 .'.k. - ' f -*M n ‘  . ................... ..............................
954 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 154 1996
TABLE 3
■ - ■ « p r i  i  i
PHYSIOLOGIC DATA OF PATIENTS WITH SARCOIDOSIS
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Definition of abbreviations: OCS = oral corticosteroids. All other abbreviations, as defined in Table 1,
* Nonsmoker.
'*■ No OCS.
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Patient Age (yr) BMI TLC RV FEVi Kco Pack- OCS
Code Sex (kg/m2) (% pred) (% pred) (% pred) (% pred) years
« — ■■ m  1 —f  - -|- -X
(mg/day)
S2 32, M 26.5 103 92 103 82
_* 25á
S3 55, F 28.7 103 75 107 117 _  +
S4 41, F 23.2 77 72 66 101 — --
S5 38, F 24.7 90 66 83 119 — 5
S6 25, F 21.5 116 122 110 76 — —
S7 32, F 30.9 85 76 91 146 — —
S8 31, M 24.2 77 58 90 127 3 —
S9 60, F 37.3 87 5 109 131 — 10
SI 0 61, F 22.6 82 82 80 125 _ 5
SI 1 33, M 20.9 78 79 53 59 16 10
SI 2 41, M 24.5 93 83 97 125 5
SI 3 59, F 27.1 93 71 111 125 —
S14 28, F 25.9 80 64 79 96 15 —
S15 43, M 27.4 90 73 86 106 -, —
SI 6 32, F 19.8 80 111 91 95 —i —
Group 1: Patients with C O P D  and control subjects. Physiologic data 
o f all individual patients are show n in Table 1. Patients were character­
ized by severe airways obstruction and (in m ost cases) hyperinflation, 
and a reduced Kco. N o improvement o f  F E V ( was observed after inha­
lation o f 400 fig salbutam ol. Patients were in a stable condition, w ith­
out exacerbations during the preceding 3 m o. A ll subjects used inhaled 
p2-sympathomimetics and/or anticholinergics. Fourteen patients (70%) 
used inhaled corticosteroids in a m ean d osage o f  630 ±  240 |o,g daily. 
None used theophylline or oral corticosteroids. Lung function data and 
body measures o f  control subjects are given in Table 4.
ery o f  the G AG s was m onitored by adding 15,000 dpm [3SS]GAGs (spe­
cific activity lO4 dpm /|j.g GAG) to the urine. Salts were removed by eth­
anol precipitation o f  the GAGs. Five volum es o f  ethanol were added
(final ethanol concentration 83% ) and GAGs were allowed to precipi­
tate for 16 h at —20° C. After centrifugation for 30 min at 10,000 g 
( -1 0 °  C), the precipitated GAGs were dried and dissolved in 2 ml deminer­
alized water. Recoveries were between 88 and 100%. Two cycles o f  freeze- 
thawing o f urine did not influence the results. A  third cycle occasionally  
gave erroneous data.
Group 2: Patients with bronchial carcinom a with an d  without em- Quantification of Glycosaminoglycans
physema. Physiologic data o f  all individual patients are shown in Tiable
2. Patients were characterized by a recently detected and histologically  
proven bronchial carcinom a (in all cases squam ous cell carcinoma). Pa­
tients with bronchial carcinoma without em physem a had no radiographic 
or histologic signs o f  em physem a, and total lung capacity and diffusion  
capacity were within predicted m ean ±  1.64 SD.
Group 3: Patients with sarcoidosis an d  control subjects. Physiologic  
data o f  all individual patients are shown in 'Bible 3. Patients had histo­
logically proven sarcoidosis stage 2 (m ediastinal an d /or  hilar lym phad- 
enopathy and radiographic signs o f  interstitial involvement). Six o f  15 
patients used oral corticosteroids in a d osage o f  5 to 25 m g/d , whereas 
the other patients did not receive any m edication. Lung function data  
and body measures o f  control subjects are given in Table 5.
Purification of Glycosaminoglycans from Urine
Urines were collected and stored at - 7 0 °  C. A fter thawing, 20-ml sam ­
ples o f  urine were diluted with an equal volum e o f  7 M urea/10 mM  
Tris-HCl pH 6.8 and applied to an ion-exchange colum n o f  5 x  0.5 cm
containing 1 ml diethylaminoethyl (D EA E)-Sepharose Fast Flow (Phar­
macia, Uppsala, Sweden). A fter an initial wash with 3 ml 0.2 M N aC l/10  
mM Tris-HCl (pH 6.8), GAGs were eluted with 1 ml 2 M N aC l/10  mM  
Tris-HCl (pH 6.8) followed by 3 ml 10 mM  Tris-HCl (pH 6.8). The recov-
Sulfated GAGs were quantified according to the m ethod o f  Farndale 
and coworkers (23). This method is based on a m etachrom atic shift in 
absorption m axim um  o f  1,9-dimethylmethylene blue (D M M B) (Aldrich  
ChemieCo., Bornem, Belgium). To 100 |4.1 GAG sample, 2.5 ml o f  DM M B  
reagent was added and the absorbance at 525 nm was measured im m edi­
ately. The D M M B  reagent contains 46 |xM D M M B (initially 46 ixmol 
DMMB was dissolved in 5 ml 96% ethanol), 40 mM  glycine, and 42 
mM NaCl, adjusted to pH 3.0 with 1 M HC1. Chondroitin 4-sulfate  
(Sigma, St. Louis, M O) was taken as a standard and included within  
each series o f  assays.
Quantification of Total Heparan Sulfate
Three m ethods for the determ ination o f  H S were used. These m ethods 
are based on different aspects o f  the HS structure. Bovine kidney HS  
(Seikagaku, Tokyo, Japan) was used as a standard.
M ethod 1 is a m odified  version o f  the 1,9-dimethylmethylene blue 
assay and is based on  the backbone structure o f  heparan sulfate (24). 
Addition o f  bovine serum  albumin and adaptation o f  pH  and salt co n ­
centration o f  the D M M B  reagent results in a specific elim ination o f  HS- 
based absorbance. To 100 p-1 GAG sam ple, 100 fxl 3% bovine serum al­
bumin (BSA) (in demineralized water) and 2.4 ml o f  the modified DM M B
TABLE 4 TABLE 5
LUNG FUNCTION DATA AND BODY MEASURES OF 
CONTROL SUBJECTS IN GROUP 1 (AGE, 51-85 YR)
BMI, kg/m2 
TLC, % pred 
FRC, % pred 
RV, % pred 
FEVi, % pred 
Kco, % pred
24,5 ±4.1 
106 ± 14 
116 ± 26 
110± 39 
94 ±21 
92 ± 31
* - • 1 - ---- ............ . .......................... ...........................wv'U'.l*
For definition of abbreviations, see Table 1. 
* Values are mean ± SD (n = 24).
LUNG FUNCTION DATA AND BODY MEASURES OF 
CONTROL SUBJECTS OF GROUP 3 (AGE, 28-61)*
BMI, kg/m 
TLC, % pred 
FRC, % pred 
RV, % pred 
FEVi, % pred 
Kco, % pred
24.4 ± 3.9 
108 ± 14 
106 ±22  
112 it 34 
108 ± 29 
105 ± 33
For definition of abbreviations, see Table 1. 
* Values are mean ± SD (n = 37).
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reagent was added. This reagent contains 48 p.M D M M B  (initially 48 
limol DM M B was dissolved in 5 ml 95% ethanol), 42 mM  glycine, and  
63 inM NaCl, adjusted to pH  2.75 with 1 M HC1. A fter 30 m in at 22° C  
the absorbance was measured at 525 nm. By subtracting the value thus 
obtained (representing other GAGs) from the total GAGs, the content 
o f  HS was calculated (24).
M ethod 2, digestion o f  H S by heparitinase, is based on cleavage o f  
glycosidic linkages in HS involving glucuronic acid residues. To lyophy- 
lized GAG sam ples, 25 |il heparitinase (Seikagaku, Tokyo, Japan) (0.01 
IU /m l containing 0.05 M sodium  acetate and 0.05 M calcium  acetate  
[pH 7.0]) was added. Incubation was for 16 h at 43 ° C. T he remaining  
GAGs were quantified  using the 1,9-dim ethylm ethylene blue assay (see  
quantification o f  GAGs). By subtracting this value from the total GAGs 
the content o f  H S was determined.
M ethod 3, digestion with nitrous acid, is based on cleavage o f  g lyco­
sidic linkages involving hexosam ine residues in which the am ino groups 
are either N-sulfated or unsubstituted. Nitrous acid digests H S and hepa­
rin, but not other GAGs (25). P urified  GAGs were treated for 90 m in  
at 22° C with nitrous acid prepared by m ixing equal volum es o f  5%  
(w t/vol) N a N O z and 1.5 M HC1. T he residual GAGs were quantified  
using the 1,9-dimethylmethylene blue assay (see quantification o f  GAGs). 
By subtracting this value from the the total GAG the content o f  H S and  
heparin was obtained. The contribution  o f  heparin is negligible.
Quantification of the HS JM403 Epitope
The HS JM403 epitope, defined by m onoclonal antibody (m A b) JM 403  
(26,27), was quantitated using an inhibition enzyme immunoassay (Figure 
1). In the wells o f  polystyrene m icrotiter plates (Greiner G m bH , Frick - 
enhausen, Germany; catalog num ber 655061), 100 p.1 o f  ascites conta in ­
ing mAb JM 403 (diluted 1:40,000 in Tris-buffered saline containing 0.1% 
Tween 20 and 1% [w t/vol] bovine serum album in, pH  7.5 [T B ST/B SA ]) 
was mixed w ith  100 |xl Iyophylized GAG sam ple and incubated over­
night at 4° C. We transferred 100 jxi o f  each well to a corresponding  
well o f  a polystyrene plate previously coated with 1 ug H S and incubated
ng HS
Figure 7. Standard curve for the inhibition immunoassay for the hepa­
ran sulfate epitope JM403. A volume of 100 ia.1 containing various 
amounts of bovine kidney HS was incubated for 16 h at 4° C with 
50 |jJ of JM403 antibody. Next, 100 |j,l of this mixture was transferred 
to a well previously coated with 1 |ag HS. After incubation for 2 h 
at 22° C, the antibodies bound to the well were detected by addi­
tion of alkaline phosphatase-conjugated secondary antibodies. Af­
ter addition of substrate the color developed was spectrophotometri- 
cally measured at 405 nm. Data are mean ± SD (n = 3).
for 2 h. Free antibodies, i.e., antibodies not bou n d  by H S o f  the sam ple, 
were allowed in this way to com plex with the coated  HS. A fter washing  
thrice with TBST, bound antibodies were detected by incubation  for 1 h 
at 22° C with 100 (j,l rabbit anti-m ouse Ig (D ako, G lostrup, D enm ark) 
conjugated w ith alkaline phosphatase (diluted 1:2,000 in T B ST /B SA ). 
After washing again, 100 p,l o f  substrate (1 m g/m l p-nitrophenylphosphate 
in 1 M diethanolam ine (pH 9.8) containing 50 m M  M gC l2) was added, 
and the reaction was allowed to proceed for 2 h at 22° C. T h e  color  
developed was spectrophotometrically measured at 405 nm. Bovine kidney 
H S was taken as a standard within each series. O ne unit is d efin ed  as 
the am ount o f  epitope present on 1 jig bovine kidney heparan sulfate.
Sam ples were analyzed in triple and at least three different tw ofo ld  
dilutions were applied such that three points were in the steep part o f  
the standard curve. Samples o f  patients and control subjects were ana­
lyzed on the sam e microtiter plate. The intra- and interassay coefficients  
o f  variation were 5.2 and 12.6%, respectively.
Other Procedures
creatinine was determined using the alkaline picrate m ethod  
(procedure number 555; Sigm a, St. Louis, M O ).
Statistical Analysis
Values are given as mean ±  SEM, unless indicated otherwise. Intergroup  
com parison was calculated using the M ann-W hitney test. C orrelation  
analysis was performed using Spearman’s rank correlation test. P values 
less than 0.05 were considered significant.
RESULTS
Pilot experiments showed that the urinary content o f HS JM403 
epitope and o f HS on base of creatinine remained constant dur­
ing the day, and from day to day. This also holds for GAGs, which 
is in agreement with data from the literature (28). There was no 
correlation between age and urinary content o f  HS and GAG. 
There was, however, a correlation between age and content o f  
HS JM403 epitope (r = 0.26, p < 0.03).
In patients with COPD the content o f urinary GAGs was not 
altered compared with controls (Figure 2, Table 6). The urinary 
content of HS, measured by three different methods, was also 
not changed (Figure 3, Table 6). The urinary content o f  the HS 
JM403 epitope was significantly decreased in patients with COPD 
(Figure 4, Table 6).
To examine the specificity of this finding, we studied two ad­
ditional groups of patients: patients with bronchial carcinoma 
with and without emphysema, and patients with sarcoidosis. The
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Figure 2. Glycosaminoglycan content in the urine of individual con­
trol subjects and patients with COPD. Open squares: control; dosed 
squares: patient with COPD.
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TA B LE  6
URINARY CO N TEN T  O F  G LYC O SA M IN O G LYCA N S ,  
HEPARAN SULFATE, AN D  HEPARAN  SU LFATE  JM 403 EP ITOPE OF
CO N TRO L  SUBJECTS A N D  PAT IENTS W ITH  C O P D ★
Content Controls Patients
(per mg creatinine) (n = 20-24) (n = 20) Significance
Glycosaminoglycan, \xg 12.7 ± 0.9 11.9 ± 1.1 NS
Heparan sulfate
Modified DMMB assay, n>g 5.1 ± 0.5 5.0 ± 0.5 NS
Heparitinase assay, \ig 5.1 ±0 .7 6.4 ± 0.8 NS
Nitrous acid assay, \ig 3.3 ±0 .5 3.8 ± 0.4 NS
JM403 epitope, U 4.1 ±0 .7 0.6 ± 0.1 p < 0.0001
NS = not significant
* Values are mean ± SD SEM. Characteristics of control subjects are given in Table 4, 
of patients in Table 1.
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urinary content of the HS JM403 epitope was significantly lower 
in patients with bronchial carcinoma with emphysema compared 
with patients with bronchial carcinoma without emphysema (Fig­
ure 5, Table 7). Urinary GAG and HS content were not different 
(Table 7). Patients with bronchial carcinoma without emphysema 
had similar HS JM403 values as control subjects.
In urines of sarcoidosis patients no altered content of the HS 
JM403 epitope was found (Figure 6, Table 8). Urinary GAG and 
HS concentration were also not changed (Table 8).
DISCUSSION
In the urine of patients with COPD we found a decreased con­
tent of the HS JM403 epitope together with a normal content 
of HS. The major group o f patients studied (Group 1) was iden­
tified on a clinical basis, including lung function tests, and had 
a strong reduction of predicted FEVi. Although we had no histo­
logic evidence, the presence o f emphysema is likely in the lungs 
of patients with COPD (29). In addition, the group of patients 
with bronchial carcinoma with histologically proven emphysema 
showed a reduced content o f the HS JM403 epitope.
All values were normalized to the creatinine content, but 
COPD patients often have a reduced concentration o f creatinine 
in the urine because of reduced muscle mass (29). Correcting for 
this would result in a downward adjustment of the values for 
COPD patients. This would make the difference between the HS 
JM403/mg creatinine values o f control subjects and COPD pa­
tients even greater. A decreased HS JM403 value as a result o f  
blocking o f the epitope by a component present in the urine is 
unlikely, since prior to analysis, urine samples were first diluted 
with an equal volume of 7 M urea/10 mM Ttis-HCl. Urea is a 
chaotropic agent which disrupts noncovalent bonds. GAGs were 
subsequently purified using ion-exchange chromatography.
The specificity of the decreased HS JM403 value in COPD 
patients was confirmed by data o f two additional groups of pa­
tients (patients with bronchial carcinoma with and without em­
physema, and patients with sarcoidosis). Because all but one pa­
tient in the group of bronchial carcinoma are smokers, a major 
effect of smoking is not likely. Likewise, a major effect of medi­
cation is also unlikely because the group of patients with sar­
coidosis who received oral corticosteroids had no decrease of uri­
nary HS JM403 epitope. The content o f HS determined with three 
different assays, based on different aspects of the HS molecule, 
showed no significant differences between patients and control 
subjects. Differences in urinary GAG and HS content, however, 
may be obscured by the relatively small contribution of GAG 
and HS derived from the lung. The amount o f lung-derived HS
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Figure 3. Heparan sulfate content in the urine of individual control 
subjects and patients with COPD measured using (A) a modified 1,9- 
dimethylmethylene blue assay; (S) nitrous acid digestion; (C) hepa- 
ritinase digestion. Open squares: control; closed squares: patient with
COPD.
tope is basement membrane specific (26). In lung the propor­
tion of JM403 epitope per milligram of HS is quite high, e.g.,
JM403 epitope may, however, be quite substantial. Lung paren- in rat lung 35-fold higher than in kidney and heart (Van Den
chyma is rich in basement membranes and the HS JM403 epi- Born and coworkers, unpublished data).
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Figure 4. Heparan sulfate JM403 epitope content in the urine of in­
dividual control subjects and patients with COPD. One unit is de­
fined as the amount of epitope present on 1 p,g bovine kidney hepa­
ran sulfate. Open squares: control; closed squares: patient with COPD.
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Figure 6. Heparan sulfate JM403 epitope content in the urine of in­
dividual control subjects and patients with sarcoidosis. Open squares: 
control; closed squares: patient with sarcoidosis.
The normal content of HS and the decreased content of the urines of emphysema patients hints at a small, but significant
HS JM403 epitope, suggest a structural alteration in or an al- alteration. Alterations in the HS molecule would have conse-
tered processing of the HS molecule in the lungs of emphysema- quences for the protecting HS-proteoglycan barrier of the al- 
tous patients. At present, we do not know the exact nature of veolus (14). In view of the functions o f HS (antiprotease activ- 
the epitope recognized by the JM403 antibody. Studies on chem- ity> binding and modulation o f growth factors and cytokines,
ically and enzymatically modified HS indicate that the epitope 
contains one or more iV-unsubstituted glucosamine and D-glu
involvement in the fibrillogenesis of collagen and elastin), this 
could lead to a destabilization of the extracellular matrix, ulti-
curonic acid units, and is located in a region of the heparan sul- mately resulting in emphysematous lesions. This concept is sup- 
fate chain composed of mixed 7V-sulfated and N-acetylated dis- ported by the findings in rats that specific inhibition of proteogly-
accharide units (30). The biologic significance of iV-unsubstituted 
glucosamines has recently been demonstrated in the binding of
can synthesis induces emphysematous lesions (33) and that HS 
proteoglycans are very vulnerable toward elastase degradation
HS to L-selectin (31). Blocking o f  the epitope in the glomerular (34). In a genetic model for emphysema, the tight-skin mouse,
basement membrane by injection of JM403 antibody leads to 
proteinuria in rats (27). Interestingly, microalbuminuria has re­
cently been described in a small group o f patients with COPD 
(32).
The etiology of pulmonary emphysema is not known. Con­
sidering that the development of (clinically evident) emphysema 
is a process o f several decades, the basic alteration may be quan­
titatively small in nature. The decreased content of a specific epi­
tope of HS, together with a normal content of total HS, in the
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Figure 5. Heparan sulfate JM403 epitope content in the urine of in­
dividual patients with bronchial carcinoma with and without emphy­
sema. Open squares: patient without emphysema; dosed squares: pa­
tient with emphysema.
antibodies to HS have been detected (35).
TABLE 7
URINARY CONTENT OF GLYCOSAMINOCLYCANS, HEPARAN 
SULFATE, AND HEPARAN SULFATE JM403 EPITOPE OF PATIENTS
WITH BRONCHIAL CARCINOMA WITH 
AND WITHOUT EMPHYSEMA*
’ .-.Hi h h. r t  - — ■ â i n i j t h ■« *  * i h  i * - * t - r i v  r\ i  f n  w i  i l l  ~ r  * 1 * 1 1 ^ 1  * a .
Patients without Patients with
Content Emphysema Emphysema
(per mg creatinine)
i _f 1  f-* *— |_■ | ii11-  ^ __it  ii^ 1 a rV, "Tt M dt t > ' i i ' l
(n = 8)
ii —1 ‘i —■ r-j .^h ik* l-’ f i  *-1 .  n i i if ■ r.*» i < 11 'ir- ‘r'li'i. i _i- ■ “ tA > fc*
(n = 7)
n /HV)#.<hi SS>^ . lyH^»L'.*|C->VI T*** AC« WW'
Significance
Glycosaminogiycan, jjtg 16.7 ±2.4 16.5 ± 2.2 NS
Heparan sulfate
Modified DMMB assay, \xg 6.4 ±0.7 6,6 ± 0.7 NS
Epitope JM403, U 2.4 ± 0.5 0.4 ± 0.1 p < 0,0005
• •  K , » v  J i t  V I  .1 I 1  A  ‘  •  ,*A< ^ . „ ‘ 4 t. sV  - i - , „  t  ^  I  .  ■ : • • •  | .  w  -  : -  — *1.  -L-. r  f  '  '<! , " L ' " I ' * ' ' " * * * L f W  i - t - V - C -  * , < > > •  . - . K . 1- ,  -  , V !  , v . . .  i . » i / -«■»«« ■'VI • v . w « " * ' - ' - «  » ' ‘ . ' J l ' - '  > !» * * » .♦ .  I ' l ' t K  A »-* A k - « «  - •  ' “ - r  > « « r » r
NS = not significant,
* Values are mean ±SEM. Characteristics of patients are given in Table 2.
TABLE 8
URINARY CONTENT OF GLYCOSAMINOGLYCANS, HEPARAN 
SULFATE, AND HEPARAN SULFATE JM403 EPITOPE OF CONTROL
SUBJECTS AND PATIENTS WITH SARCOIDOSIS
tt* w I r t . '  ................... '• f  «II<~W u«>»»<» rAv.1 I <ti.
Content Controls Patients
(per mg creatinine) (n = 41)
rr’" I».j  ‘J I- J . . . » -■—
(n = 15) Significance
Glycosaminoglycan, f^ g 14.3 ± 0.5 12.8 ± 0.9 NS
Heparan sulfate
Modified DMMB assay, fig 4.3 ± 0.3 3.0 ± 1.0 NS
Epitope JM403, U 2,4 ± 0,4 1.7 ±0.2 NS
NS = not significant.
* Values are mean±SEM, Characteristics of control subjects are given in Table 5, of 
patients in Table 3.
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In conclusion, urines from patients with COP D/emphysema 
contain normal levels of GAGs and HS, but on the excreted HS 
the expression of a specific epitope is decreased. Considering the 
physiologic role of HS in alveoli, this alteration may be associated 
with the pathogenesis of emphysema. Future research will focus 
on structural analysis of heparan sulfate from the lung paren­
chyma of patients with emphysema and on the usefulness of the 
HS JM403 epitope for early diagnosis of emphysema.
Acknowledgment: The writers express their gratitude to Ronald Moers for ex­
cellent practical assistance.
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